PDCD1 and metastatic melanoma: In patients with metastatic melanoma, intratumoral sotigalimab in combination with systemic anti–programmed cell death protein 1 (PD-1) resulted in upregulation of antigen presentation molecules, increased infiltration of effector T cells, and expansion of new T cell clones shared between injected and noninjected tumors associated with clinical benefit (9).